The INPULSIS trials of idiopathic pulmonary fibrosis treatment: explaining further discrepancies on exacerbations.


In a recent paper on the INPULSIS trials, two duplicate 1-year randomised controlled trials evaluating nintedanib in the treatment of idiopathic pulmonary fibrosis (IPF) [1], we provided the methodological explanation for the apparent inconsistent results arising from the two different definitions of exacerbations used in those studies [2]. These trials… (More)
DOI: 10.1183/13993003.01274-2015


1 Figure or Table

Slides referencing similar topics